Relapsing-Remitting Multiple Sclerosis - Ocrevus
Living with Relapsing-Remitting Multiple Sclerosis means navigating a condition that is unpredictable by nature. Finding the right RRMS treatment is not a one-time decision – it is an ongoing commitment that demands the very best in medical expertise and monitoring. At Lone Star Neurology in Texas, we are currently enrolling participants in a significant Ocrevus clinical trial evaluating a biosimilar, ABP 692. Sponsored by Amgen, this study is designed to compare the effectiveness and safety of ABP 692 with those of the established brand-name medication Ocrelizumab.
The primary objective of this Ocrelizumab clinical trial is to demonstrate that the biosimilar performs equivalently to the original drug in suppressing new active brain lesions over 24 weeks, as measured by MRI. The study also evaluates how the body processes the medication (pharmacokinetics) and how the medication affects the body’s systems (pharmacodynamics). Total study duration is approximately 64 weeks.
If you have been searching for an MS clinical trial near me, this is a meaningful opportunity to access specialized neurological care at no cost while actively contributing to the future of relapsing-remitting MS treatment. We are looking for eligible participants who are ready to take an informed, active role in managing their health. Call us today at 214-619-1910 or apply online to find out whether you qualify.
What Is Relapsing-Remitting MS (RRMS)?
Relapsing-Remitting Multiple Sclerosis is the most prevalent form of MS and the one most commonly requiring ongoing RRMS medication. It is defined by clearly distinct “relapses” – episodes during which new or worsening neurological symptoms emerge – followed by periods of “remission,” during which symptoms may partially or fully resolve.
During a relapse, the immune system attacks the myelin sheath that protects nerve fibers in the central nervous system. This inflammatory process can produce a broad and disruptive range of symptoms, including:
- Extreme fatigue that persists regardless of rest
- Numbness, tingling, or a burning sensation in the limbs
- Blurred or double vision
- Difficulties with balance, coordination, and walking
- Cognitive fog or significant trouble with concentration
The day-to-day impact of relapsing-remitting MS can be profound. The unpredictability of relapses makes it genuinely difficult to plan for work responsibilities, family commitments, or social engagements. That is precisely why identifying an effective relapsing-remitting MS treatment is so critical. The ultimate goal of any therapy is to reduce relapse frequency, prevent the formation of new lesions in the brain and spinal cord, and preserve patient independence for as long as possible.
About the ABP 692 / Ocrevus Research Study
This study focuses specifically on a biosimilar called ABP 692. A biosimilar is a biological medicine that is highly similar – in structure, function, and clinical performance – to an already approved biological drug. In this case, researchers are comparing ABP 692 directly to Ocrelizumab (Ocrevus) sourced from both the US and EU markets, ensuring a rigorous, internationally valid comparison.
This multiple sclerosis research study at Lone Star Neurology is designed to confirm that the biosimilar is as effective as the original. Over the 64-week study period, participants undergo a structured series of assessments to track their neurological progress. The primary measurement window is the first 24 weeks, during which frequent MRI scans monitor the degree to which active brain lesion formation is suppressed.
Participation in this Ocrelizumab clinical trial is entirely voluntary. Should you choose to enroll, your experience will include:
- Regular scheduled infusion visits
- High-resolution MRI imaging at defined intervals
- Comprehensive neurological and safety evaluations throughout
Every participant is closely monitored by a team of board-certified specialists, providing a level of individualized oversight that consistently exceeds what is available through standard clinical care.
Who May Be Eligible?
Strict eligibility criteria are in place to protect participant safety and ensure the scientific integrity of the data. You may be eligible for this RRMS treatment study if you meet the following requirements:
- Age. You must be between 18 and 60 years old.
- Diagnosis. You have been formally diagnosed with RRMS according to the revised 2017 McDonald Criteria.
- Disability Status. Your EDSS (Expanded Disability Status Scale) score falls between 0 and 5.5.
- Disease Activity. You must satisfy at least one of the following: two or more documented relapses within the past two years; one documented relapse within the past 12 months; or at least one T1 gadolinium-enhancing MS-related lesion on MRI within the past six months.
- Stability. Your condition must currently be stable, with no new or worsening symptoms in the preceding 28 days.
These represent the general screening parameters. Our clinical study team determines final eligibility following a comprehensive individual screening process. If this profile reflects your current situation, this MS clinical trial near you is well worth exploring.
What to Expect as a Study Participant
Enrolling in a clinical study is a significant decision, and our team at Lone Star Neurology is committed to ensuring you feel informed and supported at every stage.
Your journey begins with a thorough screening visit that includes a review of your medical history and a baseline MRI. Once enrolled, you will move into the active treatment phase, which involves scheduled infusion visits during which the study medication is administered under specialist supervision. Regular MRI assessments continue throughout the treatment period to evaluate the impact on lesion activity. The final phase of the study is a structured safety follow-up that extends through week 64.
When patients consider their available MS treatment options, many find that the structured, closely monitored environment of a clinical trial provides a level of attention and care that is difficult to replicate in routine outpatient settings. At Lone Star Neurology, you are not a number in a database – you are a patient receiving high-level, individualized neurological care from physicians who are genuinely invested in your outcomes.
Benefits and Risks of Participation
Every medical study involves an honest balance of potential benefits and risks. We encourage every prospective participant to weigh these carefully before making a decision.
Potential benefits include:
- Access to treatment. You receive the investigational biosimilar and all study-related care at absolutely no personal cost.
- Advanced monitoring. Frequent, high-quality MRI scans and detailed neurological assessments provide an exceptionally clear picture of your disease status throughout the year.
- Contributing to science. Your participation directly advances a multiple sclerosis research study that could lead to more affordable and accessible RRMS medication options for patients worldwide.
Potential risks to consider:
- Side effects. As with the reference drug, participants should be aware of potential Ocrevus side effects. These most commonly include infusion-related reactions such as itching, redness, or mild rash, as well as a modestly elevated risk of infections – particularly respiratory tract infections.
- Time commitment. Active participation requires regular clinic visits over approximately 64 weeks, a meaningful time commitment.
Our clinical team will discuss every one of these factors with you in full during your initial consultation, ensuring you have all the information you need to make a confident, well-informed decision.
How to Apply - Contact Lone Star Neurology
If you are ready to explore this opportunity, getting started is straightforward. We are actively enrolling and welcome your inquiry. You can begin by completing our online application form, which includes a brief set of initial screening questions:
- Your name and phone number
- Are you between the ages of 18 and 60?
- Have you been diagnosed with RRMS per the 2017 McDonald Criteria?
- Does your EDSS score fall between 0 and 5.5?
- Do you meet the relapse or MRI activity criteria outlined above?
- Has your condition been stable for the past 28 days?
Once submitted, a dedicated study coordinator from Lone Star Neurology will contact you promptly to discuss next steps and answer any questions about this clinical trial near me.
For full technical details, the study is listed on ClinicalTrials.gov under identifier NCT06700343.
Contact Lone Star Neurology:
- Phone: 214-619-1910
- Status: Currently Enrolling
Participating in a clinical trial is one of the most proactive steps you can take in managing your condition. We look forward to hearing from you and helping you navigate your MS treatment options with confidence and clarity.